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KILLING US SOFTLY: HOW SUB-
THERAPEUTIC DOSING OF LIVESTOCK 
CAUSES DRUG-RESISTANT BACTERIA IN 
HUMANS 
Ariele Lessing* 
Abstract: This Note explores antibiotic-resistant bacterial strains in humans 
and their roots in American industrial livestock practices. Factory farms 
promote the growth of antibiotic-resistant bacteria—or “superbugs” —by 
giving animals subtherapeutic doses of antibiotics to prevent the diseases 
that result from confinement and unhygienic conditions. Although Con-
gress has repeatedly attempted to pass legislation to curtail the use of sub-
therapeutic antibiotic dosing in livestock, those efforts have yielded little 
change for nearly a decade. Similarly, the Food and Drug Administration 
(FDA) has stood by while antibiotic-resistance in human bacteria has ex-
ploded into a critical public health issue. This Note advocates for citizen ac-
tion under the Administrative Procedure Act to prompt the FDA to with-
draw animal approval for antibiotics that are important to human health. A 
citizen petition has a greater chance of success today than in past years due 
to the newly available scientific data and international recognition of the 
dangers of the overuse of antibiotics in factory farming. 
Introduction 
 For the latter part of the twentieth century, American farm policies 
and meat processing industries have sacrificed human health for the 
economic efficiency of industrialized livestock production.1 Doctors, 
scientists, and journalists have watched and protested as drug-resistant 
strains of bacteria, known sensationally as “superbugs,” have become 
increasingly prominent in hospitals and areas surrounding livestock 
operations.2 These superbugs—such as dangerous antibiotic-resistant 
                                                                                                                      
* Executive Editor, Boston College Environmental Affairs Law Review 2009–
2010. 
1 See, e.g., Doug Gurian-Sherman, Union of Concerned Scientists, CAFOs Un-
covered: The Untold Costs of Confined Animal Feeding Operations 2, 5 (2008). 
2 See Nicholas D. Kristof, Our Pigs, Our Food, Our Health, N.Y. Times, Mar. 12, 2009, at A29 
(reporting on the increased rates of drug resistant bacterial infections in America and link-
ing that increase to Midwest hog farms’ practice of feeding antibiotics to their livestock). 
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staphylococcus (staph) infections3 and vancomycin4-resistant bacteria— 
are emerging, claiming the health and lives of Americans every year.5 
In what Nicholas D. Kristof terms an “unconscionable” manner, Con-
gress and the Food and Drug Administration (FDA) promote the 
growth of superbugs by permitting agribusiness to use sub-therapeutic 
levels of antibiotics in order to safely keep large numbers of food ani-
mals in confined, unsanitary conditions.6 
 The precipitous rise in antibiotic-resistant strains of bacteria in the 
last few decades is due to the large amounts of sub-therapeutic doses of 
antibiotics being fed to livestock on industrial animal farms.7 The move 
from small, family-owned farms to large, industrial factory farms has 
resulted in farmers tightly packing their animals together in order to 
increase their profits.8 However, the competition among farmers to 
produce as much animal food product as possible necessitates the use 
of sub-therapeutic doses of antibiotics to keep livestock healthy and 
productive.9 In recent decades, studies have shown that the practice of 
administering sub-therapeutic doses of antibiotics to animals contrib-
utes to strains of antibiotic-resistant bacteria in humans.10 These antibi-
otic-resistant strains of bacteria cause humans to become more viru-
lently ill for longer periods of time than their antibiotic-susceptible 
                                                                                                                      
3 ST398—a virulent strain of methicillin-resistant Staphylococcus aureus (MRSA). Id. 
4 Vancomycin is an antibiotic used to treat staphylococcal infections that are resistant 
to other forms of antibiotics and to treat humans with penicillin allergies. Baxter Health-
care Corp., Fact Sheet on Vancomycin Hydrochloride Injection, Solution 5 (2009), avail-
able at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050671s014lbl.pdf. 
5 See Robyn L. Goforth & Carol R. Goforth, Appropriate Regulation of Antibiotics in Live-
stock Feed, 28 B.C. Envtl. Aff. L. Rev. 39, 41 (2000); Nicholas D. Kristof, Pathogens in Our 
Pork, N.Y. Times, Mar. 15, 2009, at WK13. 
6 Kristof, supra note 5. But see Preservation of Antibiotics for Medical Treatment Act of 
2009, H.R. 1549, 111th Cong. (2009); Press Release, Keep Antibiotics Working, Rep. 
Slaughter Reintroduces Bill to Help Fight Antibiotic Resistance Crisis by Combating Mis-
use of Antibiotics in Animal Agriculture (Mar. 17, 2009), available at http://www.keepan- 
tibioticsworking.com/new/resources_library.cfm?RefID=105489 [hereinafter Rep. Slaugh-
ter Press Release] (reporting that Rep. Slaughter of New York reintroduced a bill designed 
to fight antibiotic resistance—the Preservation of Antibiotics for Medical Treatment Act—
in March of 2009). 
7 Kristof, supra note 5; see U.S. Gen. Accounting Office [GAO], Food Safety: The 
Agricultural Use of Antibiotics and Its Implications for Human Health 4 (1999). 
8 See Goforth & Goforth, supra note 5, at 46 n.48 (summarizing Barbara O’Brien, 
Comment, Animal Welfare Reform and the Magic Bullet: The Use and Abuse of Subtherapeutic 
Doses of Antibiotics in Livestock, 67 U. Colo. L. Rev. 407, 412–13 (1996)). 
9 See id. 
10 See Michael Barza et al., Introduction to The Need to Improve Antimicrobial Use 
in Agriculture: Ecological and Human Health Consequences, at S74 (Michael Bar-
za & Sherwood L. Gorbach eds., 2002). 
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counterparts.11 When humans contract these more potent diseases, 
they are ill for a longer period of time; consequently, they suffer the 
physical and emotional burden of prolonged illness and death. They 
also put a larger financial burden on the public health system.12 
 Neither the legislature nor the FDA has been able to properly deal 
with the problem of sub-therapeutic livestock dosing and its creation of 
superbugs.13 This Note proposes citizen action through an FDA citizen 
petition as a viable solution to congressional and administrative inac-
tion on the dangers that excessive antibiotic use in animals poses to 
public health.14 Such a petition, filed under the authority of the Ad-
ministrative Procedure Act (APA), would ideally prompt the FDA to 
withdraw approval for certain antibiotics crucial to human health.15 
Were the FDA to deny the petition, this Note further illustrates how a 
citizens’ group would successfully navigate an action for judicial review 
to compel the FDA to act.16 
 Part I of this Note explores the history of factory farming in Amer-
ica and how the practice of sub-therapeutic dosing of food animals miti-
gates the inherent problems with industrial farming.17 Part II conveys 
how antibiotic resistance occurs and how antibiotic resistance moves 
from food animals to humans.18 Part III discusses proposed legislation 
and FDA action to curtail antibiotic use in livestock.19 Part IV addresses 
the process of FDA petitions and judicial review of agency inaction.20 
                                                                                                                      
11 See id. 
12 See id. It is estimated that the cost of treating patients with disease-resistant strains of 
antibiotics might be as high as $30 billion annually. Robyn Mallon, The Deplorable Standard 
of Living Faced by Farmed Animals in America’s Meat Industry and How to Improve Conditions by 
Eliminating the Corporate Farm, 9 Mich. St. J. Med. & L. 389, 399 (2005). 
13 See Preservation of Antibiotics for Medical Treatment Act of 2007, H.R. 962, 110th 
Cong. (2007); Preservation of Antibiotics for Medical Treatment Act of 2005, S. 742, 109th 
Cong. (2005); Preservation of Antibiotics for Medical Treatment Act of 2003, S. 1460, 
108th Cong. (2003); Vanessa K.S. Briceño, Superbug Me: The FDA’s Role in the Fight Against 
Antibiotic Resistance, 9 N.Y.U. J. Legis. & Pub. Pol’y 521, 532–33 (2005) (discussing pro-
posed solutions and the need for more effective remedies). Although Briceño spoke hope-
fully of the PAMTA bill, that bill was never passed into law, illustrating Congress’s inability 
so far to solve the problem of sub-therapeutic antibiotic dosing in agriculture. Kristof, su-
pra note 5. 
14 See 21 C.F.R. § 10.30 (2009). 
15 See Administrative Procedure Act § 4(d), 5 U.S.C. § 553(e) (2006). 
16 See infra Part V. 
17 See infra Part I. 
18 See infra Part II. 
19 See infra Part III. 
20 See infra Part IV. 
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Finally, Part V analyzes how a citizens group might successfully challenge 
FDA inaction regarding animal antibiotic use under the APA.21 
I. The Growth of Industrial Animal Husbandry 
A. From Family Farm to Factory Farm 
 Before World War II, farming practices in the United States fo-
cused on small, family-owned farms, which produced multiple animal 
products from diverse livestock in amounts sufficient to subsist.22 This 
practice allowed the animals and the land to work together so that 
farms continued producing food indefinitely without damage to the 
health of their ecosystems.23 The symbiotic relationship between ani-
mal and land was effective because animals were fed by neighboring 
crops on the same farm while certain plots lay fallow.24 Animal wastes 
were recycled back onto the fallow plots whose nutrients had been de-
pleted by crops in previous seasons.25 In addition to the improved land 
conditions from family farming, the animals themselves were given 
enough room to grow, exercise, and socially interact with other animals 
according to their behavioral needs.26 
 The traditional style of farming began to change in the 1940s when 
farming practices shifted their focus to streamlined, assembly-line pro-
duction of animal food products.27 Farmers developed technology that 
allowed animals to live in specialized indoor environments in which an-
imals’ dietary, physical, and social needs were largely ignored.28 Ani-
mals’ natural needs became a liability to the farmer because they did 
not conform to the technological standards of the machines that, hen-
ceforth, would process the animals into food.29 In addition to the new 
assembly-line style automation, farming in the United States became 
highly concentrated, resulting in fewer farms and greater amounts of 
                                                                                                                      
21 See infra Part V. 
22 Holly Cheever, Concentrated Animal Feeding Operations: The Bigger Picture, 5 Alb. L. 
Envtl. Outlook 43, 43 (2000). 
23 See id. at 43–44. 
24 See id. 
25 See id. 
26 See id. at 43. 
27 See id. at 44. 
28 See Cheever, supra note 22, at 45; Jonny Frank, Note, Factory Farming: An Imminent 
Clash Between Animal Rights Activists and Agribusiness, 7 B.C. Envtl. Aff. L. Rev. 423, 427–30 
(1979) (describing the changes that chickens and hogs undergo in order to modify the 
animals’ natural needs to the practices of the factory farm). 
29 See Frank, supra note 28, at 424. 
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livestock.30 Today, factory farms are run more like industries than the 
mini-ecosystems of traditional family farms.31 At any given time, factory 
farms—which are known as animal feeding operations (AFOs)—raise 
hundreds, thousands, or even millions of animals in confinement.32 
 Two main problems emerging from the density of AFOs are the 
enormous amounts of waste produced by the animals and the propen-
sity of the animals to become diseased.33 Certain AFOs that contain an 
extremely large number of animals are known as concentrated animal 
feeding operations (CAFOs).34 For larger animals, such as cows, CAFOs 
contain at least 1000 animals while for smaller animals, such as chick-
ens, CAFOs may house tens of thousands of animals.35 In addition to 
the density of animals within each individual CAFO, groups of CAFOs 
tend to be concentrated in certain parts of the country, exacerbating 
the environmental hazards that arise from these livestock factories.36 
Because of the concentration of animals in each CAFO and the geo-
graphic concentration of the CAFOs themselves, farmers require even 
more technology to manage the problems that began to arise from the 
confinement of so many animals.37 
B. The Legacy of Factory Farming: Waste and Disease 
 Animal waste imposes a negative environmental impact on the sur-
rounding air and water.38 The total amount of waste produced by Amer-
ican factory farms is estimated to average 500 million tons of manure 
each year, or roughly three times the total human waste produced in the 
United States. These high levels of animal waste require special holding 
                                                                                                                      
30 See Gurian-Sherman, supra note 1, at 2; Cheever, supra note 22, at 44. 
31 Frank, supra note 28, at 424. 
32 Sarah C. Wilson, Comment, Hogwash! Why Industrial Animal Agriculture Is Not Beyond 
the Scope of Clean Air Act Regulation, 24 Pace Envtl. L. Rev. 439, 440 (2007). 
33 See Cheever, supra note 22, at 44–45. 
34 Ctr. for Disease Control & Prevention, Animal Feeding Operations—Agricultural 
Water—Other Uses of Water—Healthy Water, http://www.cdc.gov/healthywater/other/ 
agricultural/afo.html (last visited May 14, 2010). CAFOs are feed lots that house a large 
number of animals in a confined area for forty-five days or more over twelve consecutive 
months. Id. 
35 Gurian-Sherman, supra note 1, at 2. 
36 See id. 
37 Cheever, supra note 22, at 44. 
38 See, e.g., Jeff L. Todd, Comment, Environmental Law: The Clean Water Act—Understanding 
When a Concentrated Animal Feeding Operation Should Obtain an NPDES Permit, 49 Okla. L. Rev. 
481, 481 (1996); Wilson, supra note 32, at 441. 
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systems, such as the manure lagoons commonly found on swine farms.39 
These manure lagoons contain the air pollutant ammonia, as well as 
water-soluble pollutants and pathogens that seep into nearby water sup-
plies and are consequently regulated under the Clean Water Act.40 
 The cramped quarters in which animals are kept and the stress of 
their unnatural lives on factory farms place them in greater danger of 
becoming diseased and behaving in aggressive and unnatural ways that 
promote injury and illness.41 Consequently, factory-farm animals are 
redesigned to minimize the dangers of infection and injury to the flock 
or herd.42 For example, battery chickens, hens raised for egg produc-
tion, are confined in only forty-eight square inches of standing room 
per chicken and undergo a process called “forced molting.”43 Forced 
molting is a way to unnaturally increase a battery chicken’s egg produc-
tion in the later stages of its life.44 First, the flock is denied food for two 
weeks.45 This starvation causes premature molting, which in turn, caus-
es the hen to enter a second season of production instead of the natu-
ral waning of the egg cycle.46 Broiler chickens, raised for their meat, are 
de-beaked in order to prevent them from attacking one another as a 
                                                                                                                      
39 See 40 C.F.R. § 122.23 (2009); see also Mallon, supra note 12, at 396 (citing a Sierra 
Club estimate that American CAFOs produce 2.7 trillion tons of waste per year). 
40 See 33 U.S.C. § 1311 (2006); Revised National Pollutant Discharge Elimination Sys-
tem Permit Regulation and Effluent Limitations Guidelines for Concentrated Animal 
Feeding Operations in Response to the Waterkeeper Decision, 73 Fed. Reg. 70,418, 70,419 
(Nov. 20, 2008) (to be codified at 40 C.F.R. pts. 9, 122, 412); GAO, Animal Agriculture: 
Information on Waste Management and Water Quality Issues 11 (1995); Terence J. 
Centner, Establishing a Rational Basis for Regulating Animal Feeding Operations: A View of the 
Evidence, 27 Vt. L. Rev. 115, 118 (2002); Wilson, supra note 32, at 441. Water-soluble pol-
lutants include an estimated 1.3 million tons of nitrogen and 700,000 tons of phosphorous 
from AFOs and CAFOs that pollute the nation’s rivers and streams each year. Centner, 
supra, at 118. These nutrients can over-stimulate algae growth in the tributaries, upsetting 
the natural ecological balance of a natural water source. See GAO, supra, at 11. While the 
extreme environmental impacts of modern factory farming are manifold, they require a 
separate analysis beyond the scope of this Note. See, e.g., Animal Feeding Operations Con-
sent Agreement and Final Order, 70 Fed. Reg. 4958, 4958 ( Jan. 31, 2005) (offering AFOs 
the chance to participate in a study of possible AFO liability under environmental statutes 
concerned with air quality, hazardous wastes, and toxic clean-up); National Pollutant Dis-
charge Elimination System Permit Regulation and Effluent Limitation Guidelines and 
Standards for Concentrated Animal Feeding Operations (CAFOs), 68 Fed. Reg. at 7176; 
Centner, supra, at 117–19; Wilson, supra note 32, at 439–42. 
41 Mallon, supra note 12, at 396–97. 
42 Cheever, supra note 22, at 45. 
43 Id. Although the USDA discourages this practice, they do not prohibit it and some 
farmers still use it. See id. at 46. 
44 Id. at 45. 
45 Id. 
46 See id. 
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reaction to their crowded confinement, poor ventilation, deficient diet, 
the presence of crippled birds in the pen.47 Veal calves endure an iron-
deficient diet—consisting of antibiotics, vitamins, and powdered milk— 
that gives their meat the pale color that makes it marketable.48 Hogs 
also exhibit aggressive behavior in reaction to overcrowding, frequently 
biting each other’s tails; farmers deal with this problem by docking the 
tails of their pigs.49 As a result of overcrowding, pigs also suffer from 
“porcine stress syndrome,” a condition analogous to human shock, 
which can cause suffering so severe that pigs have been known to die 
from the stress.50 
 The stress of modifications such as tail docking and de-beaking is 
compounded by the overcrowded conditions on CAFOs, making the 
animals perfect incubators for the growth and rapid spread of bacterial 
infections.51 Antibiotics are introduced into animal feed to combat dis-
ease and infection in order to maximize health and growth.52 
C. Sub-Therapeutic Doses of Antibiotics Mitigate the  
Stress of Factory Farm Life 
 Factory farm operations use antibiotics in feed animals for three 
main purposes: therapy for illness, to prevent disease, and to increase 
growth.53 Farmers administer antibiotics in sub-therapeutic doses when 
pursuing the latter two categories, disease prevention and growth.54 
Sub-therapeutic doses are low levels of antibiotics that are insufficient 
to kill an invading bacterial infection, but are effective in preventing 
bacterial infection from occurring.55 About 70% of all antibiotics in the 
United States are administered to animals in sub-therapeutic doses,56 
                                                                                                                      
47 O’Brien, supra note 8, at 415. 
48 See id. at 420–21. Veal calves are particularly susceptible to disease because they are 
kept in stalls so small that they have no room to defecate. Id. at 421. Instead, they sit in 
their own excrement and breathe the ammonia it produces, causing respiratory disorders 
that require yet more antibiotics to treat. See id. 
49 Id. at 418. Docking is essentially amputating the pigs’ tails. ThePigsite.com, Docking 
(Tail Clipping) Piglets, http://www.thepigsite.com/pighealth/article/555/docking-tail-
clipping-piglets (last visited May 14, 2010). 
50 Id. at 418–19. 
51 See Mallon, supra note 12, at 395–96. 
52 Id. at 399. 
53 Goforth & Goforth, supra note 5, at 45. 
54 Id. at 45–46. 
55 See Terence J. Centner, Regulating the Use of Non-Therapeutic Antibiotics in Food Animals, 
21 Geo. Int’l Envtl. L. Rev. 1, 8–10 (2008). 
56 See Press Release, Keep Antibiotics Working, EPA’s New CAFO Rule Fails to Uphold 
Agency’s Mission “To Protect Human Health,” Says National Advocacy Group (Dec. 16, 
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resulting in the administration of 15 to 18 million pounds of antibiotics 
in sub-therapeutic doses annually.57 
 Sub-therapeutic antibiotics for disease prevention are typically 
used during high risk periods for the animal, such as after weaning.58 
Animals in confinement are particularly susceptible to diseases such as 
pneumonia and diarrhea, the major causes of calf mortality, or necrotic 
enteritis, an intestinal infection in poultry.59 Today, antibiotics are ad-
ministered preemptively to all confined animals in drug-laced feed in-
stead of being prescribed by veterinarians to prevent these diseases.60 
Though antibiotics are most often used during high risk periods to 
prevent diseases, the ability to mass medicate through feed enables 
farmers to continue administering antibiotics for growth enhancement 
over the course of the animals’ lives, contributing to the development 
of drug-resistant pathogens.61 
 It appears that sub-therapeutic doses of antibiotics cause growth in 
livestock; however, the link between drug use and increased animal size 
is not well understood.62 While scientists do not fully understand how 
antibiotics improve growth, there are several possible explanations for 
the apparent relationship between weight gain and antibiotic use.63 One 
possibility is that the antibiotics mitigate the deleterious effects of dis-
eases that drain animals’ nutrient reserves, but would not otherwise be 
severe enough to warrant medical treatment.64 Another possibility is 
that the antibiotics strengthen the animals’ immune systems, better 
enabling them to fight off the low-grade diseases resulting from over-
crowding and trauma.65 Lastly, antibiotics in animal feed might alter the 
animals’ metabolic rate, resulting in weight gain.66 All three of these 
possibilities indirectly emphasize the notion that if animal hygiene was 
                                                                                                                      
2002), available at http://www.keepantibioticsworking.com/new/resources_library.cfm? 
RefID=36410 [hereinafter KAW Press Release]. 
57 Scott A. McEwan & Paula J. Fedorka-Cray, Antimicrobial Use and Resistance in Animals, 
in The Need to Improve Anitmicrobial Use in Agriculture: Ecology and Human 
Health Consequences, supra note 10, at S93, S97. 
58 Id. at S93. 
59 See id. at S95. 
60 See Mallon, supra note 12, at 399. 
61 See Gurian-Sherman, supra note 1, at 5. 
62 Pew Comm’n on Indus. Farm Animal Prod., Putting Meat on the Table: Indus-
trial Farm Animal Production in America 15 (2008). 
63 McEwan & Fedorka-Cray, supra note 57, at S98. Reports of weight gain of 1% to 11% 
of an animal’s weight indicate that antibiotics are a valuable growth promoter for the live-
stock industry. See id. 
64 See id. 
65 See id. 
66 See id. 
2010] Sub-Therapeutic Dosing of Livestock and Drug Resistant Bacteria in Humans 471 
not so poor due to congestion and stress, it might not be necessary to 
administer antibiotic drugs to animals on feed lots.67 
II. The Relationship Between Sub-Therapeutic Antibiotic 
Dosing and Human Health 
A. How Antibiotic Resistance Occurs 
 The conditions on factory farms and concentrated animal feeding 
operations (CAFOs) render them a dangerous source of antibiotic re-
sistance. Sub-therapeutic doses of antibiotics administered over long 
periods of time to a large group of animals promote natural selection 
for drug-resistant bacterial strains.68 This natural selection occurs when 
an antibiotic used to treat an infection kills off the bacteria most sus-
ceptible to that antibiotic, leaving behind the most resistant bacteria to 
multiply and spread.69 
 Antibiotics and the problem of antibiotic resistance are best un-
derstood in light of three broad principles.70 First, antibiotics are used 
to kill bacteria, but are not used to treat illnesses arising from other 
sources, such as viruses.71 Second, “antibiotic-resistant bacteria” are bac-
teria that can cause infection and are immune to the drug typically 
used to treat that infection.72 Third, antibiotic resistance in bacteria is a 
trait that can be spread from bacterium to bacterium without exposure 
to the antibiotic.73 
                                                                                                                      
67 See id. 
68 GAO, Antibiotic Resistance: Federal Agencies Need to Better Focus Efforts 
to Address Risk to Humans from Antibiotic Use in Animals 9 (2004). 
69 See id. 
70 See Stuart B. Levy, The Antibiotic Paradox: How Miracle Drugs Are Destroy-
ing the Miracle 4–8 (1992). The term “antibiotic” traditionally refers to compounds made 
by microorganisms, whereas the term “antimicrobials” refers to synthetically derived com-
pounds that perform the same function as antibiotics. Paul Ebner, CAFOs and Public Health: 
The Fate of Unabsorbed Antibiotics, Purdue Extension, Feb. 2007, at 1, 1, http://www.ces.pur- 
due.edu/extmedia/ID/ID-348-W.pdf. Factory farms use both antibiotics and antimicrobials, 
and this Note will refer to them collectively as “antibiotics.” 
71 See Levy, supra note 70, at 4; U.S. Food & Drug Admin., Antibiotic Resistance: How Mi-
suse of Antibiotics Could Threaten Your Health, FDA & You: News for Health Educators 
and Students, Winter/Spring 2009, at 1, 2, available at http://www.premierinc.com/ 
safety/safety-share/02-09-downloads/4_FDA-antibx-issue-16.pdf. 
72 See Levy, supra note 70, at 7. 
73 See id. at 8; Thomas F. O’Brien, Emergence, Spread, and Environmental Effect of Antim-
icrobial Resistance: How Use of an Antimicrobial Anywhere Can Increase Resistance to Any Antim-
icrobial Anywhere Else, in The Need To Improve Antimicrobial Use in Agriculture: Eco-
logical and Human Consequences, supra note 10, at S78, S79. 
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 Antibiotic resistance can occur in two different ways: it can happen 
spontaneously as the result of genetic mutation in bacteria’s genetic 
makeup or the resistance can be transmitted from bacterium to bacte-
rium by genetic vectors such as plasmids, which are extra-chromosomal 
DNA molecules.74 A strain of bacteria that is not resistant to an antibi-
otic—a “susceptible strain” —differs from a strain that is resistant to an 
antibiotic—a “resistant strain” —because the latter exhibits a resistance 
gene.75 In Darwinian fashion, resistance genes tend to link with genes 
for virulence, resulting in a co-transfer of two genes that increases a dis-
ease’s level of contagiousness and harmfulness while simultaneously 
rendering the disease immune to certain antibiotics.76 
B. Animals to Humans: The Resistance Link 
 The Center for Disease Control and the American Medical Asso-
ciation have known about the link between antibiotic use in livestock 
and antibiotic resistance in humans at least since 1984 and 2001, re-
spectively.77 According to the 2002 study by the Alliance for the Pru-
dent Use of Antibiotics (APUA) and other medical scholars who have 
written on the subject, direct, temporal, and circumstantial evidence all 
definitively show that antibiotic use in livestock causes drug resistant 
infections in humans.78 
 Primarily, scientists have discovered evidence directly tracing hu-
man infections back to specific livestock operations.79 One of the first 
indicators of this direct link between animal and human resistance was 
the 1976 study by Stuart Levy.80 This study showed the rise and fall of 
                                                                                                                      
74 O’Brien, supra note 73, at S79. 
75 Id. A resistance gene can travel on the plasmid independently of the rest of the bac-
teria’s chromosomes, allowing the resistance gene to travel from one bacterial strain to 
another, creating an entire group of different bacteria which are all resistant to the same 
antibiotic. Id. at S79–80. 
76 Michael Barza, Potential Mechanisms of Increased Disease in Humans from Antimicrobial 
Resistance in Food Animals, in The Need to Improve Antimicrobial Use in Agriculture, 
supra note 10, at S123, S124. 
77 Mallon, supra note 12, at 400. The American Medical Association spoke out against 
sub-therapeutic antibiotic use in 2001 because of its belief that antibiotics in animals posed 
a threat to human health because of the increase in the number of drug-resistant patho-
gens. Id. 
78 Keep Antibiotics Working, Fact Sheet on the Latest Science Linking Use of Antimicro-
bials in Animal Agriculture to Increasing Antimicrobial Resistance in Humans 1 (Mar. 2003), 
available at http://www.keepantibioticsworking.com/library/uploadedfiles/Scientific_Fact_ 
Sheet_Linking_Antimicrobials_i.pdf [hereinafter KAW Fact Sheet]. 
79 See Levy, supra note 70, at 145–47. 
80 Levy, supra note 70. 
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tetracycline-resistant bacteria in members of a Massachusetts farm family 
whose animals were fed with tetracycline-resistant feed.81 Tetracycline-
resistant E. coli bacteria began to appear in chickens within twenty-four 
to thirty-six hours after they were fed tetracycline-laced feed.82 Five to six 
months after the initial drug-laced feeding, tetracycline-resistant E. coli 
began appearing in the human family members working on the farm, 
even though the family members had not eaten any of the chickens and 
were not directly exposed to the tetracycline.83 A similar study showed 
the direct link between antibiotic resistant bacteria in farm animals and 
humans in a 1985 outbreak of salmonella in California.84 In that case, 
scientists traced a particular strain of multi-drug resistant salmonella 
back to a fast food restaurant, then to the meat processing plant, and 
ultimately back to the dairy farm that used an unapproved antibiotic in 
its feed.85 
 A second type of evidence seeks to show the link between resistance 
in animals and humans by illustrating that human resistance usually fol-
lows animal resistance in a particular location.86 Perhaps the most nota-
ble example of animal drug resistance causing human drug resistance is 
the American experience with fluoroquinone-resistant campylobacter.87 
Two years after the FDA approved fluoroquinolone for animal use, the 
percentage of fluoroquinolone-resistant bacteria in chickens rose to 
14%.88 During the same time period, the amount of fluoroquinolone-
resistant bacteria in humans rose from 1.3% to 10.2%.89 Similarly, in the 
Netherlands, fluoroquinolone-resistance rose in poultry from 0% to 
                                                                                                                      
81 Id. Tetracycline is a family of antibiotics that is commonly used because of its low 
toxicity and broad spectrum of activity. Id. at 146. Additionally, its properties as a growth 
enhancer for livestock were discovered in 1947 when a farmer administered chlortetracy-
cline, the first member of the tetracycline family, to his chickens and noted an increased in 
their growth rate. Id. at 138–39. 
82 Id. at 145. Illustrating the ease with which resistance genes transfer between bacterial 
strains, the chickens showed E. coli resistance to other antibiotics that they had never been 
exposed to within three months of being started on tetracycline feed. Id. 
83 See id. at 145–47. Additionally, the humans on the farm exhibited the same multi-
drug resistance as the chickens. Id. at 146–47. 
84 Morton N. Swartz, Human Diseases Caused by Foodborne Pathogens of Animal Origin, in 
The Need to Improve Antimicrobial Use in Agriculture: Ecological and Human 
Health Consequences, supra note 10, at S111, S113. 
85 Id. 
86 See KAW Fact Sheet, supra note 78, at 1–2. 
87 See Swartz, supra note 84, at S114. Campylobacter is a food-borne illness found in 
cattle, hogs, and poultry whose symptoms typically include intestinal distress. See id. at 
S111. 
88 Id. at S114. 
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14% within the same seven-year period and human infection rose from 
0% to 11%.90 The close temporal link between animal resistance and 
human resistance illustrates that the former causes the latter.91 
 There is also significant circumstantial evidence linking antibiotic 
resistance in humans to sub-therapeutic antibiotic dosing of food ani-
mals.92 Reports by the Union of Concerned Scientists show that 70% of 
all antibiotics produced in the United States are administered in sub-
therapeutic doses to livestock.93 This 70% includes the 13.5 million 
pounds of antibiotics important to human medicine that American li-
vestock producers administer.94 Antibiotics that are widely used in hu-
man medicine, such as tetracycline and penicillin, are also extensively 
used in livestock. The administration of antibiotics has contributed to 
the rise in drug resistant bacteria, notably among campylobacter, sal-
monella, and E. coli.95 
 There are three main ways in which antibiotic use—and therefore 
antibiotic resistance—in animals is transferred to humans: via food, via 
human contact with livestock, and via the environment.96 As demon-
strated by the study of a Massachusetts farm family’s contraction of tet-
racycline-resistant E. coli, humans in close contact with food animals 
are likely to pick up resistant bacteria.97 In that study, two weeks after 
the tetracycline-laced feed was introduced to the livestock for the first 
time, farm hands and family members began to secrete tetracycline-
resistant bacteria.98 Livestock workers can become infected with drug-
resistant bacteria through handling animals themselves, animal feed, or 
animal manure.99 Once the drug-resistant bacterial strain infects a farm 
worker, it can be readily transferred to family, friends, and other mem-
bers of the community.100 
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91 See id. 
92 KAW Fact Sheet, supra note 78, at 1–2. 
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 Another mode of animal to human transference is through the 
food products themselves.101 Over the course of an animal’s life on a 
factory farm, drug resistant bacteria build-up in its intestines; during 
slaughter and processing, those bacteria are released and spread to the 
processed and packaged meat.102 When someone consumes that proc-
essed and packaged meat, she also consumes drug-resistant bacterial 
strains, which then colonize in her intestines.103 The resistance gene 
will then thrive in the intestines where it can eventually cause harm by 
creating new resistant strains across different bacterial species.104 Re-
porting on this danger in 2002, Consumer Reports found that 42% of 
supermarket broiler chickens were contaminated with campylobac-
ter.105 Of that 42% of infected broiler chickens, 20% were infected with 
an antibiotic-resistant strain of the disease that can transfer to the hu-
man consumer.106 
 A third method of human transference is through the environ-
ment, most notably through contaminated water.107 As mentioned 
above, the Union of Concerned Scientists estimated that 70% of all an-
tibiotics used in the United States are administered in sub-therapeutic 
doses to livestock that are not ill.108 In most instances, these antibiotics 
will pass through the animals’ intestines, which results in as much as 
75% of the antibiotics consumed being excreted in the animals’ ma-
nure.109 American CAFOs generate 2.7 trillion pounds of manure an-
nually; manure that is stored in open manure lagoons and later spread 
as fertilizer on agricultural fields.110 This manure contains antibiotics 
and antibiotic-resistant bacteria from the animals’ intestines, and it fre-
quently leaks from the lagoons into nearby groundwater.111 Further-
more, the animal excrement from lagoons themselves and the waste 
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102 Id. 
103 KAW Fact Sheet, supra note 78, at 2. 
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105 Press Release, Consumers Union, Consumer Reports Finds Nearly Half of Chickens 
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applied to fields mix with rainwater and irrigation that falls on the 
fields, becoming runoff that enters lakes and streams, many of which 
serve as water sources for human consumption.112 
 According to Dr. Michael Barza, editor of the APUA Scientific Advi-
sory Panel, drug-resistant bacteria are a major threat to human health 
because the bacterial strains make humans sicker than non-resistant 
strains.113 Humans are rendered sicker by at least three methods: (1) 
patients taking an antibiotic are already weakened and their internal 
bacteria are disturbed, leaving them vulnerable to resistant bacterial 
strains;114 (2) patients suffer from the increased virulence of drug-
resistant bacterial strains due to the genetic linking of resistance genes 
with virulence genes;115 and (3) patients become incubators of resistant 
bacteria when their own intestinal bacteria acquire new resistance 
genes.116 
 Logically, the animal antibiotics most dangerous to human health 
are those that are important to human therapy.117 For example, fluoro-
quinolones—an important human antibiotic used in treating campylo-
bacter and salmonella infections—have been compromised as a human 
drug due to the resistance fostered by its use in poultry farming.118 The 
resistant strain of bacteria caused more hospitalizations, longer ill-
nesses, and more expensive treatment for infected patients than a non-
resistant strain of the same bacteria.119 
III. Agency Driven Action and Antibiotic Bans 
A. The Benefits of Antibiotic Bans 
 Legislative bans on the use of sub-therapeutic doses of antibiotics 
in agriculture may mitigate drug resistant bacterial infections in hu-
mans because bans reduce the levels of antibiotic-resistant bacteria in 
                                                                                                                      
112 See Todd, supra note 38, at 481. 
113 See Barza, supra note 76, at S123–24 & tbl.1. 
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117 See Preservation of Antibiotics for Medical Treatment Act of 2009, H.R. 1549, 111th 
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the environment.120 The European example is particularly telling.121 
Legislation regulating antibiotic use in animals has been enacted since 
1986, followed by bans in individual countries over the next several 
years.122 In 1998, the European Union Council Regulation 2821/98 
withdrew approval for four animal feed additives.123 This baseline was 
augmented by individual countries that have passed more stringent 
standards since the initial ban.124 After these regulations were put into 
effect, studies in Europe showed a “significant decline” in the levels of 
resistant bacteria.125 
 Although it is too soon for conclusive results, the object of the 
agency-driven fluoroquinolone ban in the United States was to lower 
the occurrence of fluoroquinolone-resistant bacteria in humans.126 In 
2005, the Food and Drug Administration (FDA) banned the use of Bay-
tril, a fluoroquinolone antibiotic, in poultry production.127 The FDA 
decided to withdraw approval for use of the drug because it was con-
tributing to the increase of antibiotic-resistant bacterial infections in 
humans.128 Baytril is chemically similar to Cipro, a drug used in hu-
mans to fight off food-borne illnesses such as campylobacter and sal-
monella.129 Use of Baytril in animals caused more strains of fluoroqui-
nolone-resistant food poisoning in humans than existed before Baytril’s 
approval for animal use, resulting in an estimated 8700 days of hospi-
talization per year.130 Because the continued use of Baytril in poultry 
production caused humans to contract Cipro-resistant infections, the 
FDA banned the drug in order to reverse the escalating number of 
Cipro-resistant strains of bacteria.131 
 The arguments against legislative bans on sub-therapeutic antibi-
otic doses usually focus on one issue: the cost to the agricultural indus-
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try of less robust animals.132 The additional costs associated with ban-
ning sub-therapeutic antibiotic use consist of the money spent on addi-
tional feed to make up for lost growth enhancement, and the increase 
in animal illness and mortality that can negatively affect yield.133 How-
ever, the validity of this argument is called into question by the Euro-
pean example, which shows that for certain producers, the additional 
cost of feed can be offset by the decrease in the cost of antibiotics.134 
 There is disagreement between industry and research institutions 
on what effect a sub-therapeutic antibiotic ban would have in the Unit-
ed States.135 For example, one American study conducted by the agri-
cultural industry projected that hog farmers would lose $0.79 per 
hog—a noticeable loss of profit—if antibiotics were no longer approved 
for use in feed.136 This study also predicted that the cost of a ban would 
increase during stressful times for the animal, such as weaning, and in 
farms with “questionable hygiene practices.”137 Another industry study, 
which focused on broiler chickens, predicted a 1.76% rise in produc-
tion costs per year if antibiotic use in feed was banned; however, a 2007 
citizens’ group study refutes that estimate.138 Instead, the citizens’ study 
finds that banning growth enhancing antibiotics actually increases the 
value of the flock.139 A possible explanation for the positive industry 
results in Europe from reduced antibiotic use is different animal hus-
bandry techniques and farm organization.140 Interestingly, in the Amer-
ican studies that found a similar benefit to the industry from reduced 
antibiotic dosing and improved hygienic practices, such as frequent 
litter changes, were directly related to lower mortality rates.141 
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B. A Study of Agency Driven Action: The Fluoroquinolone Example 
 In the case of Baytril, the FDA underwent a long and complicated 
process to ban its use in food animals.142 The FDA first proposed the 
Baytril ban in 2000, but the agricultural industry delayed the FDA’s ac-
tion for five years while the Bayer Company appealed the decision 
through various levels of administrative review.143 Ultimately, the ad-
ministrative law judge found that Bayer had not sufficiently demon-
strated that Baytril was safe for use in poultry production.144 Addition-
ally, the judge found that enrofloxacin use in poultry is a source of 
fluoroquinolone-resistant bacterial infections of campylobacter in hu-
mans that adversely affect human health.145 In 2005, the FDA success-
fully withdrew approval for Baytril; fluoroquinolones are no longer 
used in U.S. poultry production.146 
C. The Need for Citizen Driven Action 
 Though the FDA’s banning of Baytril through the Center for Vet-
erinary Medicine (CVM)—the administrative branch that makes deci-
sions regarding animal antibiotics147—is encouraging, citizens’ groups 
cannot rely on the CVM to consistently ban from animal use the re-
maining seven antibiotics that are crucial to human health.148 The fluo-
roquinolone action, while ultimately successful, is the only withdrawal 
of any animal antibiotic that the FDA has ever undertaken.149 In fact, 
the only action that the FDA has taken since the decision to ban fluo-
roquinolone in poultry use is the issuance of Guidance #152, a set of 
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guidelines for evaluating the safety of new animal antibiotics.150 Guid-
ance #152 recommends that pharmaceutical companies self-evaluate 
their drugs’ risk levels on the basis of release, exposure, and conse-
quence–a recommendation that is likely to go unheeded given the in-
dustry’s concern that the banning of animal drugs will increase costs 
and adversely impact their bottom line.151 Moreover, the FDA’s fluoro-
quinolone ban is incomplete; it only applies to the use of the drug in 
poultry, allowing its continued use in swine.152 
 Recognizing the need for uniformity and efficiency in the with-
drawal of approval for animal antibiotics, both houses of Congress pro-
posed bills to ban seven classes of antibiotics from animal use in 2003, 
2005, 2007, and 2009.153 The bill, aptly titled the Preservation of Antibi-
otics for Medical Treatment Act (PAMTA), seeks to ban the sub-
therapeutic use in animals of seven antibiotics that are important in bat-
tling human diseases.154 If passed, the 2003, 2005, and 2007 bills would 
have circumvented the FDA withdrawal process altogether,155 yet given 
the history of the 2003, 2005, and 2007 bills, it is not surprising that the 
House has not passed the 2009 reincarnation of PAMTA.156 
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 Perhaps recognizing that a bill as single-minded and straightfor-
ward as PAMTA has not been politically viable, a group of legislators in-
troduced the Food Safety Modernization Act in the House of Represen-
tatives on February 4, 2009.157 This bill, if passed, seeks to establish a 
Food Safety Administration (FSA) and FSA Administrator who would 
oversee and improve food sanitation and “food safety practices.”158 An-
other of the Administrator’s duties would be to “analyze the incidence 
of antibiotic resistance as it pertains to the food supply and develop new 
methods to reduce the transfer of antibiotic resistance to humans.”159 
While it is admirable that Congress is addressing the issue of antibiotic 
use in food animals, it has yet to successfully effect any significant 
changes in the agricultural regime that overuses antibiotics.160 Neither 
the FDA nor Congress has proven itself capable of effectively dealing 
with growing antibiotic resistance through sub-therapeutic animal dos-
ing; it is time for a citizens’ group to petition the FDA to withdraw ap-
proval for animal use of important human drugs and, if necessary, ac-
complish the same outcome through an action for judicial review.161 
IV. Citizen Petitions and Judicial Review of FDA (In)action 
A. FDA Procedure for Approval Withdrawal 
 There are two junctures in an FDA decision to withdraw approval 
for an animal drug.162 First, the Center for Veterinary Medicine (CVM) 
must determine whether to commence formal withdrawal proceedings 
for the drug.163 Second, if the CVM does initiate formal withdrawal 
proceedings, it must follow the statutory requirements for such pro-
ceedings on a drug-by-drug basis, as set out in 21 U.S.C. § 360b and 21 
C.F.R. § 514.115.164 Both provisions require that the CVM consider the 
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available scientific data to determine whether the drug is unsafe.165 If 
the CVM finds a drug to be unsafe—a phenomenon that has occurred 
only once in the history of the FDA166—CVM must notify the drug’s 
sponsor and give the sponsor an opportunity for a formal administra-
tive hearing.167 Such hearings are preceded by notice, and consist of 
formal evidentiary hearings that render a decision that can later be ap-
pealed to a U.S. Court of Appeals.168 Typically, formal withdrawal pro-
ceedings, like the one that occurred in the withdrawal of fluoroqui-
nolone approval, are prolonged and expensive.169 
B. Citizen Petitions 
 Citizens can prompt the FDA to consider withdrawal of an animal 
drug by submitting a “citizen petition.”170 Agency action or inaction is 
subject to judicial review through the Administrative Procedure Act 
(APA), which provides that federal agencies must allow interested par-
ties to petition for the repeal, modification, or creation of agency 
rules.171 To comply with the APA, the FDA has installed a process for 
judicial review through the “citizen petition,” a mechanism for petition-
ing the FDA to “issue, change or cancel a regulation, or to take other 
action.”172 The agency guidelines provide FDA staff a period of “several 
weeks to more than a year, depending on the issue’s complexity,” to 
evaluate a petition before deciding whether or not to grant it.173 How-
ever, some form of response must be furnished to the petitioner within 
180 days of receipt of the petition.174 The citizen petition allows the 
FDA to apply its agency expertise in considering the petition request 
for action before allowing the courts to intervene.175 While this period 
of evaluation is vague and leaves open the possibility that citizen peti-
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tioners might be forced to wait longer than one year for a response, the 
citizen petition is the necessary first step for citizen action prompting 
the FDA to withdraw approval for certain animal antibiotics.176 When 
the FDA eventually does make a final decision on the citizen petition, 
that action is subject to judicial review pursuant to the APA.177 
C. Reviewability of Agency Action Under the APA 
 The APA denies reviewability to two categories of decisions: 
(1) decisions where the governing statute precludes review, and 
(2) decisions where the agency is given discretion by law.178 As to the 
first category, agency action is presumed to be reviewable under the 
APA except where “clear and convincing” evidence exists that Congress 
intended to prohibit judicial review.179 Arguably, agency inaction has no 
less a presumption of reviewability because the concerns behind the 
APA rules of reviewability—maintaining procedural standards and pre-
venting careless enforcement of regulations—are equally pertinent to 
agency inaction.180 The second category of exclusion is a narrow one 
that precludes review only in “rare instances” where the governing stat-
ute is so broad that it does not establish standards to appraise the legal-
ity of an agency decision; in this case, the statute effectively provides 
“‘no law to apply.’”181 However, this situation is uncommon, given that 
governing statutes usually set out sufficient guidelines to evaluate the 
legitimacy of agency actions.182 
D. Standing 
 The APA allows a plaintiff challenging reviewable agency action or 
inaction to sue under section 704.183 However, the Case or Controversy 
Clause in Article III of the United States Constitution, as interpreted by 
the Supreme Court, limits who can sue in federal court under section 
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704.184 It requires that a plaintiff have “standing” as evidenced by three 
characteristics: (1) the plaintiff has suffered injury-in-fact; (2) that in-
jury is fairly traceable to the harm alleged; and (3) the injury will likely 
be relieved by a positive outcome.185 
 The first requirement for standing is that the plaintiff has suffered 
an injury-in-fact.186 In Lujan v. Defenders of Wildlife, the Supreme Court 
held that a “‘generalized grievance’” that is “‘undifferentiated and 
common to all members of the public’” does not entitle a plaintiff to file 
suit under Article III.187 Rather, the plaintiff must show that “the action 
injures him in a concrete and personal way.”188 However, in Friends of the 
Earth v. Laidlaw Environmental Services, the court found sufficient stand-
ing for plaintiffs who suffered particular damage to “‘aesthetic and rec-
reational values.’”189 The court held that an environmental plaintiff 
could establish injury-in-fact by proving that they used a geographic area 
that was harmed by the defendant’s activity.190 The option of establish-
ing injury-in-fact through proof that the plaintiff is geographically close 
to the harm suggests a broadening of the standing requirements for en-
vironmental plaintiffs.191 
 The second requirement for standing is that the concrete and per-
sonal injury suffered by the plaintiff has been caused by the agency ac-
tion that is the subject of the litigation.192 This requirement is straight-
forward, stipulating merely that the court must be able to follow a 
logical sequence of events from the agency action to the plaintiff’s 
harm.193 Lastly, the plaintiff must show that redress is possible through a 
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favorable decision of the courts.194 This requirement is likewise uncom-
plicated, requiring that a court-ordered cessation of defendant’s pro-
tested conduct will solve the plaintiff’s grievance.195 
V. Beyond Citizen Petitions: The Next Step 
A. Effective Standing for APA Challenge 
 Standing is likely to be the biggest obstacle facing a plaintiff chal-
lenging an unfavorable decision on a Food and Drug Administration 
(FDA) citizen petition that requests withdrawal of approval for specified 
animal antibiotics.196 Difficulty showing standing will arise primarily 
from the difficulty in showing injury-in-fact.197 Standing is a particular 
burden for plaintiffs whose harm is intangible, or not yet realized, and is 
therefore less quantifiable for the courts.198 Despite the broadening of 
the injury-in-fact standard by Friends of the Earth v. Laidlaw Environmental 
Services—where damage to “aesthetic and recreational values” created 
sufficient standing—the standing requirement for a challenge to con-
tinued FDA approval for animal antibiotics is not easy to surmount.199 
 The most problematic element to achieving standing is finding a 
plaintiff that has suffered particularized harm.200 However, following 
the slightly more relaxed approach to standing espoused in Laidlaw 
leaves room for a class of citizens that can identify a particular harm 
from an increased risk of contracting antibiotic-resistant strains of bac-
teria.201 For instance, any citizen with a compromised immune system 
would fit into a category of plaintiff with a particularized harm. Be-
cause antibiotic resistance and virulence tend to travel together, pa-
tients with acquired immune deficiency syndrome (AIDS), cancer pa-
tients undergoing chemotherapy, young children, the elderly, and any 
other person with a weakened immune system would likely be able to 
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prove a unique susceptibility to the alleged harm of contracting a drug-
resistant bacterial infection.202 
 Likewise, the dangers of contracting drug-resistant bacterial strains 
appear to be more prevalent the closer one lives to an animal feed lot.203 
In Laidlaw, the court found that citizens’ group located near the site of 
the challenged activity satisfied the injury-in-fact element of standing 
because that group’s proximity to the action caused them to suffer a 
particularized harm—loss of use of the land for recreational and aes-
thetic purposes.204 Similarly, a citizens group located near such an ani-
mal feeding operation (AFO) or concentrated animal feeding operation 
(CAFO) that uses antibiotic feed would suffer a particularized harm—a 
higher chance of contracting a drug-resistant bacteria strain from the 
proximity of the animals.205 By analogy, such a citizens group would 
have a strong argument for the particularized harm element of standing 
due to their close proximity to the source of the harm.206 
 In a case against the FDA, the second and third requirements for 
valid standing—causation and redressability—should be easier to satisfy 
than the injury-in-fact requirement. In a case regarding harm from ag-
ricultural antibiotic use, the cause of the harm alleged is not a third 
party, rather the harm is directly traceable back to the FDA’s refusal to 
withdraw approval for animal use of antibiotics now shown to be dan-
gerous to human health.207 The Union of Concerned Scientists’ 2002 
study and the European example linking antibiotics in animal use to 
higher instances of drug-resistant bacteria together should satisfy Arti-
cle III’s requirement of causation.208 Similarly, redressability is unambi-
guous in this instance because if the FDA were to withdraw approval for 
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the seven classes of antibiotics specified, the science dictates that the 
amount of drug-resistant strains of bacteria would similarly diminish.209 
B. A Citizen Petition to Withdraw Certain Animal Drug Approvals 
 The first step for an interested citizen or citizens group with stand-
ing to petition the FDA is to complete the FDA citizen petition.210 In 
the petition, the citizens group must specify the action requested, the 
grounds for the request, an environmental and economic impact 
statement where warranted, and certification that all information con-
tained in the petition is true.211 In this case, the action requested is a 
withdrawal of approval for animal use of certain antibiotic classes, the 
grounds are a threat to human health, and an economic impact state-
ment is not warranted.212 Though petitions have been filed in the past 
requesting the FDA to consider withdrawing approval for drugs impor-
tant in human health, none has led to a direct withdrawal of ap-
proval.213 While the Center for Veterinary Medicine’s (CVM) decision 
to withdraw approval for fluoroquinolone was influenced by the citizen 
petitions it received regarding the dangers of animal antibiotic use, it 
did not cite those petitions as directly prompting their investigation.214 
The citizen petition process should be taken to the next stage: judicial 
review, as provided for in the APA should be used to force the FDA to 
reconsider the decision not to ban the classes of antibiotics most crucial 
to human health for use in animals.215 
 To begin, a citizen group, such as the Center for Science in the 
Public Interest (CSPI), who filed petitions in 1999 and 2005, must sub-
mit a citizen petition requesting agency action to withdraw approval for 
the seven classes of antibiotics that have been identified as most crucial 
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to human health.216 The required “statement of grounds” section of the 
citizen petition should be modeled after the proposed Preservation of 
Antibiotics for Medical Treatment Act, which concisely lists congres-
sional findings on the dangers of antibiotic use in animals.217 Because 
the FDA, in withdrawing approval, considers new scientific information 
not known at the time of the original decision,218 the citizen petition 
should include, along with the congressional findings, the conclusions 
of the GAO reports of 1999 and 2004, the Union of Concerned Scien-
tists study of 2002 that appeared in Clinical Infectious Diseases, and any 
other relevant and reliable scientific findings made since the approval of 
these seven antibiotics.219 The statement of grounds section is the most 
persuasive part of the petition, as it is the only part of the petition where 
petitioners have an opportunity to sway the agency to make a discre-
tionary decision in their favor.220 Convincing presentation of the avail-
able science is crucial to the success of the petition.221 
 Should the FDA refuse the request of the citizen petition to ban 
the seven classes of antibiotics, that refusal is subject to judicial review 
as provided for in the APA.222 The reviewing court will interpret the 
statute under which the FDA operates to determine if the agency action 
in denying the petition was arbitrary or capricious.223 This standard is 
meant to determine whether the FDA, among other factors, “failed to 
consider an important aspect of the problem, offered an explanation 
. . . that runs counter to the evidence before the agency, or is so im-
plausible that it could not be ascribed to a difference in view.”224 
 Because of the plethora of available data on the impact of the use 
of animal antibiotics to human health225—which will have been in-
cluded in the grounds portion of the citizen petition—judicial review is 
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a particularly useful tool in the case of animal antibiotic bans.226 The 
available science that favors the plaintiffs is sound; the studies were 
conducted by reputable research institutions over a period of years, 
which gave the scientists ample opportunity to gather substantial da-
ta.227 This data convincingly categorizes the findings that sub-
therapeutic dosing of food animals with antibiotics endangers human 
health.228 Furthermore, because the data is relatively new compared to 
the data available when these seven antibiotics were approved for ani-
mal use,229 a reviewing court would likely consider the studies “new evi-
dence not contained in [the original] application or not available to 
the Secretary until after such application was approved”—a finding that 
would force the FDA to reconsider its original approval.230 
 Although courts generally show considerable deference to agen-
cies in judicial challenges to their actions,231 if a court finds the new 
information presented in the citizen petition to pertinently change the 
context in which the FDA made its initial decision, the court can force 
the FDA to institute rulemaking procedures to address the issue.232 Of 
course, the court cannot dictate the actual decision an agency makes, it 
can only ensure that the decision is made using all the available and 
applicable data.233 The goal of such judicial intervention would be to 
prompt the FDA to create rules that reflect the science, banning the 
sub-therapeutic use of seven classes of antibiotics identified as vital to 
human health.234 
Conclusion 
 It is no longer logical, as it once might have been, to deny the ef-
fect of sub-therapeutic antibiotic dosing on the rise of drug-resistant 
bacteria in America.235 Unhygienic conditions on American concen-
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trated animal feeding operations (CAFOs) lead farmers to administer 
sub-therapeutic doses of antibiotics to large groups of animals, encour-
aging a natural selection in favor of antibiotic-resistant bacteria.236 
These resistant bacterial strains are then transferred to humans 
through the animal product, through human contact with livestock, 
and through environmental channels such as a contaminated water 
supply.237 As studies in the United States and Europe prove, drug-
resistant strains of bacteria threaten human health more than non-
resistant bacteria because the former type of infections make humans 
sicker for longer periods of time than the latter.238 
 Although there is evidence that a legislative ban on the use of sub-
therapeutic doses of antibiotics in agriculture would mitigate drug re-
sistant bacterial infections in the United States as it did in Europe, the 
American agricultural industry resists such bans because of the cost to 
the farmer.239 Accordingly, Congress has yet to pass a legislative ban on 
animal antibiotics, despite the introduction of four such bills in Con-
gress.240 Another option to stop the increase of drug resistant bacteria 
is agency-driven withdrawal of approval for animal antibiotics.241 How-
ever, FDA-driven action has been limited to the 2005 fluoroquinolone 
ban and thus does not seem to be a reliable option for future regula-
tion of animal antibiotics.242 
  When Congress and the FDA refuse to act effectively, citizens can 
petition the FDA to consider withdrawing approval for animal drug use 
through the FDA petition process.243 If that petition is denied, the APA 
provides a mechanism for citizens to sue the FDA in order to force it to 
repeal, modify, or create agency rules.244 Plaintiffs must satisfy the 
Court’s prudential standing requirements.245 Of the three elements of 
standing—particularized harm, causation, and redressability—finding a 
plaintiff who has suffered particularized harm due to antibiotic use in 
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animal feed is likely to be the largest challenge.246 However, based on 
the expanded interpretation of standing in Laidlaw, two likely possibili-
ties for successful plaintiffs are patients with compromised immune sys-
tems or those living near an animal feeding operation or CAFO.247 
 A citizen petition under the APA has a significant chance of suc-
cess because of the considerable amount of newly available data on the 
negative effects of antibiotic use.248 While judges generally show defer-
ence to agencies in petitions for judicial review,249 the new information 
on how FDA inaction affects human health by promoting drug-resistant 
bacteria is likely to prompt a court to force the FDA to reconsider its 
inaction.250 This reconsideration could lead the FDA to follow the ex-
amples of Europe and its own action on fluoroquinolone and pass stric-
ter regulations on animal antibiotics to better protect Americans from 
the ravages of drug-resistant bacteria. 
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